title: Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo.
abstract: The present study was designed to investigate in vivo immunomodulatory properties of hematopoietic growth factors. The influence on the activation of cytokine synthesis and on the expression of surface antigens associated with cellular activation of G-CSF or GM-CSF was investigated in cancer patients receiving these factors. One single dose of growth factor was administered to patients with bladder cancer (G-CSF group) or small cell lung cancer (GM-CSF group) before chemotherapy. After cytoreductive chemotherapy patients received supportive therapy with G-CSF or GM-CSF. Peripheral blood mononuclear cells and plasma samples were obtained for flow cytometry, Northern blot analysis, and assessment of cytokine protein levels after single-dose as well as after continuous cytokine administration. Our results demonstrate differences in the induction of biological activities by GM-CSF and G-CSF in vivo which correlate well with in vitro findings. Among mature hematopoietic cells the effect of G-CSF is restricted to the granulocyte lineage. With GM-CSF moderate but unequivocal modulation of monocyte function was observed. On peripheral blood monocytes expression of MHC class-II molecules and CD44 was markedly stimulated. After one single dose of GM-CSF, plasma levels of sCD25 and IL-1RA were significantly induced (p < 0.0001, p = 0.032, respectively) and a trend to increased IL-8 levels was observed. The changes in plasma proteins were not correlated with shifts of mRNA expression for IL-8 and IL-1RA. T-cell activation was not observed with either cytokine. These results suggest that immunomodulatory features are differentially regulated by G-CSF and GM-CSF. The clinical relevance of a selective use of both hematopoietic growth factors in various disease settings remains to be determined.
authors.affiliation: Third Department of Internal Medicine, Johannes Gutenberg University School of Medicine, Mainz, Germany.
authors.forename: M J
authors.initials: MJ
authors.lastname: Aman
authors.forename: K
authors.initials: K
authors.lastname: Stockdreher
authors.forename: A
authors.initials: A
authors.lastname: Thews
authors.forename: K
authors.initials: K
authors.lastname: Kienast
authors.forename: W E
authors.initials: WE
authors.lastname: Aulitzky
authors.forename: L
authors.initials: L
authors.lastname: Färber
authors.forename: U
authors.initials: U
authors.lastname: Haus
authors.forename: B
authors.initials: B
authors.lastname: Koci
authors.forename: C
authors.initials: C
authors.lastname: Huber
authors.forename: C
authors.initials: C
authors.lastname: Peschel
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000954:Antigens, Surface / Q000096:biosynthesis; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006133:Growth Substances / Q000235:genetics; D006412:Hematopoietic Stem Cells / Q000737:chemistry; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008875:Middle Aged; D012333:RNA, Messenger / Q000378:metabolism; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D015375:Receptors, Interleukin-2 / Q000097:blood; D011994:Recombinant Proteins / Q000097:blood; D012795:Sialoglycoproteins / Q000097:blood; D012995:Solubility
chemical_list: D000276:Adjuvants, Immunologic; D000954:Antigens, Surface; D006133:Growth Substances; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6; D016209:Interleukin-8; D012333:RNA, Messenger; D017472:Receptors, Interleukin-1; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor